Breaking News
0

What To Watch When Teva Reports Q1 2018 Earnings On Thursday

By Investing.com (Haris Anwer/Investing.com)Stock MarketsMay 03, 2018 00:05
ca.investing.com/analysis/what-to-watch-when-teva-reports-q1-2018-earnings-on-thursday-200197014
What To Watch When Teva Reports Q1 2018 Earnings On Thursday
By Investing.com (Haris Anwer/Investing.com)   |  May 03, 2018 00:05
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
  • Reports Thursday, May 3, before the open
  • Revenue Expectation: $16.89B, EPS: $2.31


When Teva Pharmaceutical Industries (NYSE:TEVA) reports earnings for its first-quarter on May 4, don’t expect fireworks. Kare Schultz, the CEO who took the helm of the generic and specialty medicine manufacturer this past November, has been very upfront about the company’s dismal growth prospects in the near-term. His strategy, to dampen investor expectations while he works on a massive belt-tightening campaign, has so far played out in his favor.

TEVA 2015-2018
TEVA 2015-2018

Teva shares have gained more than 50% so far during his still-new tenure, attracting interest from the world’s most successful value investor, Warren Buffett, whose Berkshire Hathaway Inc. (NYSE:BRKa) initiated a new position worth about $365 million in Teva, to become its tenth largest shareholder. But that initial euphoria may evaporate quickly if Schultz fails to show the market that his restructuring plan, which involves cutting about 25% of the company’s workforce, is moving ahead as originally planned.

Slippery Downward Slope, Complex Problems

Teva’s shares have been on a slippery-slope during the past three years as the company’s $41-billion acquisition of Allergan's (NYSE:AGN) generics unit failed to improve sales. The deal went sour at a time when the company lost its monopoly on Copaxone, the multiple sclerosis injection that at one point generated half of Teva’s profits.

In February, Teva said it won’t be able to charge as much as expected for new medicines amid escalating pressure on prices in the U.S. Sales this year may decline as much as 18% to $18.3 billion, about $1 billion less than analysts had estimated.

Another key detail to look for in Teva’s earnings call is how well Schultz's efforts to manage this drug maker’s precarious debt load are succeeding. Teva has more than $17 billion of debt due over the next five years. In a recent $4.5 billion,10-year bond sale, the company was successful in extending its maturities. However, it had to offer interest rates that junk borrowers pay.

It’s clear there's no quick fix for Teva’s complex problems, especially when the U.S. pharmaceutical industry is going through drastic changes, ranging from accelerated Food and Drug Administration (FDA) approval of competing medicines to government regulation that limits drug prices.

Bottom Line

Any positive surprise on the earning front should be enough to produce a powerful rally in Teva’s stock, now that investors have almost written off any hope for recovery in 2018. That scenario, however, puts more pressure on Schultz to deliver quickly.

What To Watch When Teva Reports Q1 2018 Earnings On Thursday
 

Related Articles

What To Watch When Teva Reports Q1 2018 Earnings On Thursday

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments
Brad Smith
Brad Smith May 04, 2018 11:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very good points Haris. The $17 billion debt is likely a primary concern for many looking into Teva. The gargantuan debt puts Teva in a tougher spot against incoming headwinds such as the persistent weakness in sales.
Reply
0 0
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email